Author

M. Kohyama

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Nakagawa· 3 shared C. Ono· 3 shared H. Arase· 3 shared M. Okada· 3 shared S. Matsuoka· 3 shared W. Nakai· 3 shared Y. Liu· 3 shared Y. Matsuura· 3 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Nakagawa

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses

M. Kohyama, T. Suzuki, W. Nakai, C. Ono, S. Matsuoka, K. Iwatani, Y. Liu, Y. Sakai, A. Nakagawa, K. Tomii, K. Ohmura, M. Okada, Y. Matsuura, S. Oshima, Y. Maeda, , H. Arase

This study shows that SARS-CoV-2 ORF8 protein acts as a cytokine that promotes lung inflammation and immune dysregulation in COVID-19, suggesting it as a potential therapeutic target.

bioRxiv · Aug 1, 2022Microbiology

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

Y. Liu, N. Arase, J.-i. Kishikawa, M. Hirose, S. Li, A. Tada, S. Matsuoka, A. Arakawa, K. Akamatsu, C. Ono, H. Jin, K. Kishida, W. Nakai, M. Kohyama, A. Nakagawa, , H. Arase

The paper shows the Delta variant can escape NTD antibodies and gain infectivity when specific RBD mutations are present, suggesting the need for updated vaccines.

bioRxiv · Aug 22, 2021 · PreprintMicrobiology

An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies

Y. Liu, W. T. Soh, A. Tada, A. Arakawa, S. Matsuoka, E. E. Nakayama, S. Li, C. Ono, S. Torii, K. Kishida, H. Jin, W. Nakai, N. Arase, A. Nakagawa, Y. Shindo, , H. Arase

This study identifies an NTD site on SARS-CoV-2 spike protein that enhances infectivity when targeted by antibodies, and finds these antibodies are present in hospitalized patients and some uninfected donors.

bioRxiv · Dec 18, 2020Microbiology